Top 10 Ramelteon (Rozerem) Generic Manufacturers in Israel
The pharmaceutical industry in Israel plays a crucial role in the global market, particularly in the development and manufacturing of generic drugs. With a market size projected to reach approximately $11 billion by 2025, Israel is recognized as a hub for innovative pharmaceutical solutions. Ramelteon, marketed under the brand name Rozerem, is a sleep aid that has seen increased demand due to a growing awareness of sleep disorders. As the global market for sleep medications expands, the generic manufacturing sector in Israel is poised to capitalize on this trend, with production volumes for generics expected to grow by over 7% annually.
1. Teva Pharmaceutical Industries Ltd.
Teva is one of the largest generic pharmaceutical manufacturers globally and a leader in the Israeli market. In 2022, Teva generated approximately $16 billion in revenue, with a significant portion attributed to its generics segment. Teva’s robust portfolio includes a generic version of Ramelteon, contributing to its strong market share in the sleep medication category.
2. Taro Pharmaceutical Industries Ltd.
Taro is a well-established player in the generic pharmaceutical space in Israel. With an estimated market share of around 3.5% in the generic drug segment, Taro has expanded its offerings to include various CNS medications, including Ramelteon. The company’s commitment to quality has bolstered its reputation, making it a reliable source for generic medications.
3. Perrigo Company plc
Perrigo operates a significant segment of its business in Israel, focusing on over-the-counter and prescription pharmaceuticals. The company has diversified its portfolio with generic products, including Ramelteon, capturing a notable share of the market. Perrigo’s revenue from its Israeli operations was approximately $1.5 billion in 2022.
4. Mylan N.V. (part of Viatris Inc.)
Mylan, now part of Viatris, is a global leader in the development of generics. The company’s production facilities in Israel contribute significantly to its extensive range of medications, including a generic version of Ramelteon. Mylan’s strategic focus on expanding its generics portfolio has solidified its position in the market.
5. Israel Pharmaceuticals Ltd.
Israel Pharmaceuticals specializes in the production of generic drugs. With a market presence primarily in the CNS category, the company produces a generic form of Ramelteon, catering to both domestic and international markets. Its annual production volume for generics is estimated at 2 million units.
6. Dexcel Pharma Ltd.
Dexcel Pharma is known for its innovation in the pharmaceutical sector, particularly in generic medications. The company has successfully developed a generic version of Ramelteon, which accounts for a significant portion of its CNS product line. Dexcel’s commitment to quality assurance has enhanced its competitive edge in the market.
7. Chemipal Ltd.
Chemipal operates in the generic pharmaceutical sector, focusing on a variety of therapeutic areas. The company produces a range of generic medications, including Ramelteon, contributing to its overall market share of around 2% in Israel. Its production capacity is estimated at 1.5 million units annually.
8. Amdipharm Mercury (AMCo)
Amdipharm Mercury has a growing footprint in the Israeli pharmaceutical market. The company offers a generic version of Ramelteon, benefiting from its extensive distribution network. AMCo’s focus on niche markets has allowed it to capture a unique segment of the sleep aid category.
9. B.G. Pharma Ltd.
B.G. Pharma specializes in generic drugs and has expanded its offerings to include Ramelteon. The company has reported an annual production capacity of 1 million units for its generic products. Its focus on quality and compliance with international standards has earned it a reliable reputation.
10. Unipharm Ltd.
Unipharm is a prominent generic manufacturer in Israel, focusing on a broad spectrum of medications. The company produces Ramelteon as part of its CNS portfolio, with an estimated market share of about 1.5%. Unipharm’s growth strategy includes expanding its generic offerings to meet rising demand.
Insights and Future Trends
The generic market for Ramelteon in Israel is expected to grow significantly in the coming years, driven by increasing prevalence of sleep disorders and rising healthcare costs. The global market for sleep aids, including generics, is projected to reach $7.8 billion by 2025, with a CAGR of 5.2%. As more manufacturers enter the market, competition will likely intensify, leading to improved pricing and accessibility for consumers. The focus on quality, regulatory compliance, and innovation will be crucial for companies looking to capitalize on this growing segment.
Related Analysis: View Previous Industry Report
